 Phase 3 pivotal study succeeds in endpoints using ARCT-154 for Covid-19; Emergency Use Authorization submitted to Vietnam with possible approval for use in coming weeksmonths. Ability to expand ARCT-154 in the Covid-19 booster treatment market space; Company already received feedback from several regulators for such a pivotal booster study for Covid-19. 